Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Lyra Therapeutics, Inc. (LYRA)
Company Research
Source: GlobeNewswire
WATERTOWN, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today announced that it has granted non-qualified stock options to purchase a total of 119,200 shares of Lyra common stock to 18 new non-executive employees as an inducement material to their acceptance of employment with Lyra. The employment inducement awards were approved by Lyra’s independent directors serving on its Compensation Committee and granted under the Company’s 2022 Inducement Award Plan, as amended, and related form of stock option agreement in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Lyra, or following a bona fide period of non-employment, as an inducement material to such indivi
Show less
Read more
Impact Snapshot
Event Time:
LYRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LYRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LYRA alerts
High impacting Lyra Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LYRA
News
- Lyra Therapeutics, Inc. (NASDAQ: LYRA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire
- Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
LYRA
Earnings
- 8/8/23 - Beat
LYRA
Sec Filings
- 4/30/24 - Form 10-Q
- 4/30/24 - Form 8-K
- 4/29/24 - Form DEFA14A
- LYRA's page on the SEC website